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Objective To determine whether a nonintervention approach for treating hemodynamically significant patent ductus
arteriosus (PDA) is associated with decreased mortality and/or morbidity compared with a mandatory closure ap-
proach in extremely low birth weight infants.
Study design We reviewed the medical records of 178 infants of 23-26 weeks’ gestational age with PDA, re-
quiring ventilator treatment, and with hemodynamically significant PDA ≥2 mm in size. Mandatory closure was used
during period I (July 2009 to December 2011, n = 81), and nonintervention was used during period II (January 2012
to June 2014, n = 97).
Results During period I, 64% of infants were first treated with indomethacin, and 82% were ultimately ligated surgi-
cally. During period II, no infant was treated with indomethacin and/or ligation. The average postnatal day of PDA closure
was day 13 and day 44 during periods I and II, respectively. There was significantly more use of diuretics and fluid re-
striction during period II compared with period I. There was no difference in mortality or morbidities such as necrotizing
enterocolitis or intraventricular hemorrhage. The incidence of bronchopulmonary dysplasia (BPD) and the propensity
score adjusted OR of BPD were significantly lower during period II compared with period I.
Conclusions Despite longer PDA exposure, nonintervention was associated with significantly less BPD compared
with mandatory closure. Additional study is warranted to determine the benefits and risks of non-intervention for the he-
modynamically significant PDA in extremely low birth weight infants. (J Pediatr 2016;177:66-71).
Patent ductus arteriosus (PDA) in preterm infants is associated with increased mortality and morbidities such as bron-chopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), and intraventricular hemorrhage (IVH)1; however, acausal relationship has not been established. Although it is traditional to manage PDA with cyclooxygenase inhibitors
and/or surgical ligation, definite evidence supporting the benefit of these PDA therapies over watchful waiting with supportive
care is lacking,2-4 and they might be associated with adverse effects on multiple organ systems.5,6 There are emerging concerns
about morbidity associated with surgical ligation, especially in the most immature babies and in the first week of life.7-9 The
question of whether mandatory PDA closure therapy is more beneficial than conservative nonintervention that allows spon-
taneous closure remains unanswered.2,3,10
The paucity of published data regarding supportive care of PDA4,11-13 has created challenges in generating rational, evidence-
based management of PDAs in very premature infants. In our neonatal intensive care unit (NICU), the policy for manage-
ment of a hemodynamically significant patent ductus arteriosus (HS-PDA) in extremely preterm infants with gestational age
(GA) of 23-26 weeks has evolved as follows: between July 2009 and December 2011 (period I), a mandatory PDA closure ap-
proach via indomethacin and/or surgical ligation was conducted. Surgical ligation was performed as primary treatment when
the indomethacin was contraindicated and as secondary treatment when indomethacin treatment failed. From January 2012
to June 2014 (period II), the PDA management strategy changed to a nonintervention approach without targeted pharmaco-
logic or surgical treatment regardless of the hemodynamic significance. The change was prompted by literature review, the in-
creasing concerns about the risks of early surgical ligation, and the observation that less-invasive treatment appeared to be tolerated
in preterm infants <27 weeks of age who did not require early ventilator support.4,11-13 In the present retrospective observa-
tional study, we reviewed the medical records of preterm infants of 23-26 weeks’ gestation with HS-PDA to determine whether
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our change from a mandatory closure to a nonintervention
approach was associated with improved or worsened adverse
outcomes in the most immature infants.
Methods
Data collection was approved by the Institutional Review Board
of Samsung Medical Center (SMC), which allowed a waiver
of informed consent for this retrospective chart review (IRB
No. SMC 2013-02-129). The medical records of 178 of 250
preterm infants with GA of 23-26 weeks born and admitted
to the SMC NICU and presenting with HS-PDA were re-
viewed retrospectively. The details of 72 infants excluded from
analysis are shown in Figure 1 (available at www.jpeds.com).
After admission to the NICU, infants were examined daily
in the first 2 weeks for changes in respiratory support and clini-
cal symptoms/signs related to HS-PDA, including deteriora-
tion in respiratory condition, cardiac murmur, hyperactive
precordium, hypotension, and widened pulse pressure. If any
of these were found, a 2-dimensional echocardiogram
(ACUSON Sequoia C512; Siemens Medical Solutions, Moun-
tain View, California) was performed within 48 hours. If domi-
nant left-to-right flow (by gain-optimized color Doppler)
through a PDA 2 mm or more in size was found, these symp-
toms and signs could be regarded as due to symptomatic PDA.
However, we did not treat extubated infants regardless of PDA
size on echocardiography throughout the study period.
During the study period, 2 distinctly different approaches
were used for the management of HS-PDA, with no changes
in strategies for respiratory support for extremely low
birth weight (ELBW) infants. In period I (July 1, 2009, to
December 31, 2011, n = 81), all ELBW infants with HS-PDA,
defined as ≥2 mm with predominant left-to-right shunt by
echocardiography, and receiving ventilator support with
symptoms/signs suggestive of PDAhadmandatoryPDAclosure.
Mandatory closure was initiated with intravenous indometha-
cin treatment (0.2 mg/kg for the initial dose and 2 subsequent
doses of 0.2 mg/kg/dose every 12 hours), usually at the end of
the first week to avoid unnecessary drug exposure, as a 30%
spontaneous closure rate at postnatal day 7 has been re-
ported, even in infants with birth weight <1000 g.14 Early sur-
gical ligation was performed as soon as possible if the PDA
failed to close with 1 or 2 cycles of intravenous indomethacin,
or if indomethacin treatment was contraindicated. The deci-
sion for the ligation was made by the attending neonatolo-
gists, based on clinical judgment thatmedical therapy had failed
or a contraindication for indomethacin treatment existed. Li-
gationdidnotdependon strict echocardiographic criteria,except
for PDA size (≥2 mm).
In period II (January 1, 2012 to June 30, 2014, n = 97), we
changed our treatment strategy to a nonintervention ap-
proach. Infants were first managed with judicious fluid re-
striction and pro re nata (PRN) diuretics with respiratory
support as needed. Treatment with indomethacin or ligation
was reserved as a last resort, and no infant with HS-PDA re-
ceived either therapy during period II.
Among infants who had a smaller PDA size (<2 mm) or who
did not require ventilator support within the first 2 weeks of
life, 2 infants received later indomethacin treatment in the third
and fourth week of life. Both infants experienced a sudden de-
terioration of respiratory condition, including reintubation after
previous weaning from the ventilator, and simultaneously in-
creased PDA size to more than 2 mm.They ultimately had PDA
closure within 2 weeks after indomethacin treatment.
Clinical characteristics including GA, birth weight, Apgar
scores at 1 and 5 minutes, sex, small for gestational age, mode
of delivery, chorioamnionitis, pulmonary hemorrhage, and an-
tenatal steroid use, days of nasogastric feeding, and data on
weight z score at discharge were analyzed. GA was deter-
mined by maternal last menstrual period and the modified
Ballard test. Small for gestational age was defined when birth
weight was less than the tenth percentile. Chorioamnionitis was
confirmed by placental pathology. Pulmonary hemorrhage was
defined as presenting with bloody fluid from the endotra-
cheal tube plus radiologic suggestion of pulmonary hemor-
rhage developing within the first week of life. Oliguric renal
failure was defined as urine output of less than 0.5 mL/kg/
day for ≥24 hours combined with a serum creatinine level of
2.0 mg/dL or greater. Nonoliguric renal dysfunction was defined
as a serum creatinine level of 2.0 mg/dL or greater without oli-
guria. Diuretic use was defined as use of diuretics for at least
3 days during the first 2 weeks of life.Maximum levels of blood
urea nitrogen and serum creatinine during the first 2 weeks
of life were compared between periods. Use of inotropic drugs
was defined as use of dopamine and/or dobutamine for ≥24
hours within the first 2 weeks of life.
Outcome measures included death before discharge, BPD,
defined as the need for supplemental oxygen and/or positive
pressure to maintain oxygen saturation >90% at 36 weeks’
gestation,15 IVH (grade ≥3),16 periventricular leukomalacia,NEC
(>Bell stage IIb),17 and retinopathy of prematurity (stage ≥3).18
Duration of invasive mechanical ventilation, continuous posi-
tive airway pressure, and supplemental oxygen therapy (low
flow nasal cannula) were recorded. The data for long-term
neurodevelopmental outcome were not collected in this study.
To demonstrate the natural time course of HS-PDA accord-
ing to differences in management, the cumulative incidence
rates of ductal patency were analyzed during periods I and II.
A propensity score-adjusted regression model was used to cal-
culate aORs for mortality, BPD, and composite BPD or death
in period II vs period I with 95% CIs.
Statistical Analyses
Statistical differences between the study periods were calcu-
lated with c2 tests for categorical variables and a t test or Mann-
Whitney U test for quantitative variables. For the propensity
score-adjusted regression model, logistic regression adjusted
for propensity score was used as a covariate. The cumulative
incidence rates of ductal patency were analyzed with the Kaplan-
Meier estimation, and differences between the 2 periods were
analyzed by Cox proportional-hazards regression. Propen-
sity score included GA, birth weight, male, small for gestational
age, use of antenatal steroids, and Apgar score at 5 minutes.
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A P value of <.05 was considered statistically significant. Sta-
tistical analysis was executed with SAS version 9.4 (SAS In-
stitute, Cary, North Carolina) and R 3.0.3 (Vienna, Austria;
http://www.R-project.org/).
Results
Table I shows demographic and clinical findings of infants with
HS-PDA during periods I and II. The use of inotropic drugs
for ≥24 hours within the first 2 weeks of life was significantly
lower during period II compared with period I. Increased use
of inotropic drugs during period I compared with period II
was attributed to postoperative myocardial dysfunction (5
infants in period I vs 0 infants in period II). Other variables,
including GA,were not significantly different between the study
periods.
Treatment of HS-PDA
During period I, 52 (64%) of a total of 81 infants with HS-
PDA received intravenous indomethacin at an average post-
natal day of 7. Only 15 of 52 (29%) infants responded to
pharmacologic treatment, and the remaining 37 of 52 (71%)
infants received surgical ligation due to failure of pharmaco-
logic treatment. Because of contraindications to pharmaco-
logic treatment, 29 of 81 (36%) infants were treated with
surgical ligation only. A total of 66 of 81(82%) infants ulti-
mately received surgical ligation (Table I and Figure 1). During
period II, the age of diagnosis was slightly but significantly
delayed compared with period I (6.4 vs 5.6 days), and the size
of HS-PDA was similar. All infants were managed only with
fluid restriction, and no infants received indomethacin or li-
gation treatment.
Fate of HS-PDA
The postnatal age of PDA closure during hospitalization was
markedly delayed during period II compared with period I (44.2
vs 12.9 days; Table I and Figure 2). During period I, 1 infant
did not experience PDA closure after receiving indometha-
cin treatment but was weaned from the ventilator and stabi-
lized without further indomethacin treatment. During period
II, 5 infants (5%) were discharged without PDA closure. On
follow-up, 3 of 5 infants during period II had spontaneous
ductus closure by echocardiography done at 4, 5, and 9 months
of postnatal age. In the remaining infants, the PDA was closed
by transcatheter occlusion at 10, 12, and 13 months of age,
respectively.
Fluid Intake, Energy Intake, and Renal Function
Energy intake and renal function were similar between the 2
study periods. Fluid intake at postnatal days 14 and 21 was sig-
nificantly lower, and the use of diuretics within the first 2 weeks
was significantly greater during period II compared with period
I (Table II; available at www.jpeds.com).
Table I. Clinical characteristics of infants with HS-PDA
during periods I and II






GA, wk 24.6 ± 1.1 24.5 ± 1.0
Birth weight, g 728 ± 134 718 ± 137
Male, n (%) 35 (43) 54 (56)
Small for gestational age,
n (%)
8 (10) 8 (8)
Cesarean delivery, n (%) 68 (84) 76 (78)
Antenatal steroids, n (%) 69 (85) 79 (81)
Chorioamnionitis, n (%) 50 (63) 56 (58)
Apgar score, 1 min 4.7 ± 1.5 4.5 ± 1.4
Apgar score, 5 min 7.2 ± 1.4 6.9 ± 1.4
Pulmonary hemorrhage
during first week, n (%)
5 (6) 2 (2)
Use of inotropic drugs, n (%) 20 (25) 16 (16)*
First enteral feeding, d 1 ± 1 1 ± 1
Full enteral feeding
(>120 mL/kg/day), d
58 ± 28 57 ± 34
Body weight at discharge
(z score)
−5.9 ± 0.7 −5.8 ± 1.1
Body weight at corrected
age of 12 mo (z score)
−1.7 ± 0.9 −1.9 ± 1.0
Burden and treatment of HS-PDA
Age at first diagnosis, d 5.6 ± 1.8 6.4 ± 2.3*
PDA size at diagnosis,
mm (min-max)
2.6 ± 0.5 (2.0 - 3.8) 2.5 ± 0.5 (2.0 - 4.2)
Age of PDA closure, d 12.9 ± 12.3 44.3 ± 30.1*
PDA open until discharge,
n (%)
1 (1) 5 (5)




Age at first indomethacin, d 7 ± 5
Surgical ligation, n (%) 66 (82)
Age at ligation, d 12 ± 7
*P < .05 compared with period I.
Figure 2. Cumulative incidence rate of ductal patency during
hospitalization in infants with initial HS-PDA according to study
period.
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Adverse Outcomes
During period II, the incidence of BPD, defined as requiring
supplemental oxygen and/or positive pressure to maintain
oxygen saturation>90%at 36weeks’ gestation,durationof nasal
continuous positive airway pressure, and supplemental oxygen
were significantly lower compared with period I (Table III).
The incidence of other adverse outcomes, including mortal-
ity, IVH (grade 3 and 4), cystic periventricular leukomalacia,
retinopathy of prematurity (stage ≥3), and NEC (stage ≥IIb),
were not significantly different between the study periods.
Propensity Score aORs
The propensity score aORs of the nonintervention approach
during period II over the mandatory closure approach during
period I were aOR 0.8 (95% CI 0.3-2.2) for mortality, aOR 0.4
(95% CI 0.2-0.8) for BPD, and aOR 0.5 (95% CI 0.2-0.9) for
composite BPD or mortality in infants with HS-PDA. Al-
though the OR for mortality (OR 0.8, 95% CI 0.3~2.2) was
not significantly different, the ORs of the nonintervention ap-
proach during period II for BPD (OR 0.4, 95% CI 0.2~0.8)
and composite BPD or mortality (OR 0.5, 95% CI 0.2~0.9)
were significantly lower compared with the mandatory closure
approach during period I.
Discussion
Appropriate management of the HS-PDA, especially in very
premature infants, is an ongoing challenge. Recent compre-
hensive reviews have not provided definite evidence that early
traditional PDA treatments have greater benefit for prema-
ture infants compared with alternative supportive strategies such
as fluid restriction.2,3,10 Furthermore, some studies suggest that
reduced ligation might improve PDA outcomes.19-21 In the
present retrospective observational study, all ELBW infants with
HS-PDA, defined as ≥2 mm and receiving ventilator support,
were treated actively with indomethacin and/or ligation via a
mandatory PDA closure approach during period I. During
period II, we observed that spontaneous but later closure of
HS-PDA was achieved in most infants with a noninterven-
tion approach consisting of fluid restriction and PRN diuret-
ics without indomethacin or ligation.Despite later PDA closure,
nonintervention was not associated with increased mortality
or morbidities such as NEC or IVH, and the incidence of BPD
was significantly reduced compared with mandatory closure.
These findings suggest that nonintervention might be a rea-
sonable alternative to mandatory closure in extremely preterm
infants with HS-PDA. Our findings also support the need for
future prospective randomized trials to reexamine the pros and
cons of different approaches to HS-PDA treatment in very
preterm infants.
The lack of a standardized method to diagnose HS-PDA
makes its clinical impact and contribution to preterm mor-
bidities difficult to define. In this study, the PDA diameter and
the need for the invasive ventilator support were used to de-
termine whether to treat a PDA with indomethacin and/or li-
gation during period I. During period II, however, spontaneous
closure of HS-PDAs was achieved in 95% of infants with the
nonintervention approach without increases in mortality or
morbidities. The development of new diagnostic tools, in-
cluding clinical, biochemical, and echocardiographic findings,9,22
is necessary to better identify infants with HS-PDA requiring
specific treatment.5,23,24
During period I, indomethacin was begun on day 7 to avoid
unnecessary drug exposure.14 Only 29% of these infants re-
sponded to indomethacin treatment, and the rest were treated
with ligation.When we included those initially treated surgi-
cally, 82% of infants receiving the mandatory PDA closure ap-
proach were surgically ligated. Similar to our data, Dani et al25
reported that infants with GA of 23-25 weeks had a high risk
of developing PDA refractory to ibuprofen treatment, and
Jhaveri et al19 reported that 81% of infants at 24-25 weeks’ ges-
tation ultimately were treated with surgical ligation. Our in-
domethacin failure rate and the resultant high surgical ligation
rate might be attributable to the younger GA population in
this study.19,25 Thus, our study also compared the therapeutic
efficacy of “ultimate surgical ligation” vs “no treatment” in ex-
tremely preterm infants of 23-26 weeks’ gestation with HS-PDA.
Few studies have reported the natural history of PDA in ex-
tremely preterm infants. Rolland et al26 observed a spontane-
ous PDA closure rate of 60% in infants of 24-25 weeks’ gestation
at an average of 61 postnatal days. Herrman et al11 reported
that 86% (18/21) of very low birth weight infants with a per-
sistent PDA at discharge were spontaneously closed at 48 weeks’
gestation, with 2 infants undergoing coil occlusion at 11months
of age. In the present study, we were more stringent in the use
of indomethacin and/or ligation with the nonintervention ap-
proach during period II compared with other conservative PDA
treatment studies,4,11-13,19-21 and no infants during period II were
treated with indomethacin and/or ligation. Spontaneous closure
occurred at a mean age of 44 ± 30.1 days, with 5 (5%) infants
discharged with persistent PDA. Of these, 2 (2%) infants
Table III. Adverse outcomes of infants with HS-PDA
during periods I and II





Mortality during hospitalization, n (%) 9 (11) 9 (9)
IVH (≥ grade 3), n (%) 15 (19) 12 (12)
Cystic periventricular leukomalacia, n (%) 12 (15) 15 (16)
ROP (≥ stage 3), n (%) 5 (6) 7 (7)
NEC (≥ stage IIb), n (%) 10 (13) 12 (12)
NEC perforation, n (%) 8 (10) 8 (8)
Spontaneous intestinal perforation, n (%) 2 (3) 2 (2)
Sepsis, n (%) 18 (22) 28 (29)
Respiratory outcome
BPD, n (%) 46 (58) 35 (38)*
Duration of invasive mechanical ventilation 32 ± 23 38 ± 22
Duration of HFOV 19 ± 15 24 ± 17*
Duration of NCPAP 41 ± 22 34 ± 20*
Duration of supplemental oxygen 12 ± 17 6 ± 18*
Discharge with home oxygen, n (%) 10 (12) 7 (7)
HFOV, high-frequency oscillatory ventilation; NCPAP, nasal continuous positive airway pres-
sure; ROP, retinopathy of prematurity.
*P < .05 compared with period I.
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required coil occlusion after discharge. Our findings suggest
that nonintervention might be equally effective in very preterm
infants with HS-PDA.
Besides “watchful waiting,” the nonintervention approach
for HS-PDA included fluid restriction and the use of inter-
mittent diuretics. High fluid intake of >170 mL/kg/day has been
associated with an increased risk of neonatal morbidities such
as persistent PDA,27,28 driving the use of high humidified in-
cubators to decrease total fluid intake during the first week of
life in ELBW infants.29 Our data indicate that even lower fluid
intakes of ≤107 mL/kg/day during the first week of life could
be achieved without restricting caloric intake (Table II) and
without electrolyte or renal disturbances.30 Replication of our
results with a nonintervention approach might depend on
similar fluid intake goals for the first 3 weeks of life (Table II).
We also observed more use of inotropic drugs during period
I, given for postoperative myocardial dysfunction and possi-
bly indicating a higher rate of PDA treatment complications
after surgical ligation.
Later closure of HS-PDA with prolonged left-to-right ductal
shunt in very preterm infants might increase the risk of mor-
bidities such as NEC, IVH, and BPD.4,31-34 Even though PDA
closure occurred at a much later postnatal age after nonin-
tervention, there were no significant differences in mortality
and morbidities such as NEC and IVH (≥3), and a signifi-
cantly lower incidence of BPD was observed. Although phar-
macologic closure improved pulmonary mechanics and
increased alveolar growth in premature baboons with a per-
sistent PDA,35 these beneficial effects were abolished with sur-
gical ligation.8,36 Taken together, these findings raise the
possibility that the detrimental effects of surgical ligation might
outweigh the benefit derived from PDA closure.37 Thus, sur-
gical ligation might directly contribute to the development
of BPD what it is intended to prevent.5,38,39 The more pro-
longed use of high-frequency oscillatory ventilation during
period II also may have contributed to the lower incidence
of BPD.40
A prospective, randomized clinical trial of pharmacologic
vs no treatment could answer whether more prolonged ex-
posure to HS-PDA leads to BPD or other morbidities in very
preterm infants. Our data showing the favorable outcome of
nonintervention lends support to the safety and possible ef-
ficacy of a “no treatment” control group. We are thus con-
ducting a prospective, double-blind randomized controlled trial
comparing the therapeutic efficacy of “exclusive pharmaco-
logic treatment with oral ibuprofen” vs ”placebo” therapy
(ClinicalTrials.gov ID, NCT02128191).
The limitations of the present study include the single-
center, retrospective, and noncontrolled observational study
design, as well as arbitrary criteria for HS-PDA defined only
by PDA size and ventilator dependency. Variations in clinical
management policies during periods I and II, including re-
spiratory management, fluid administration, and use of di-
uretics might be other confounding variables. We also
acknowledge the lack of long-term neurodevelopmental
outcome data. Future prospective double blind trials will clarify
these issues. We also suggest the need to develop robust
definitions of echocardiographically significant PDA as well
as improved pharmacologic approaches.
In conclusion, although closure of a HS-PDA was more
delayed, a nonintervention approach of judicious fluid re-
striction and PRN use of diuretics without indomethacin and/
or ligation was not associated with increased mortality or
morbidities such as NEC or IVH (≥3). Nonintervention was
also associated with significantly less BPD compared with man-
datory closure. These findings warrant a future, prospective,
randomized study to determine the short and long-term ben-
efits and risks of nonintervention for HS-PDA in very preterm
infants. ■
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Figure 1. Study population.
Table II. Fluid intake, energy intake, and renal function in infants with HSPDA during periods I and II
Total (n = 178)
Period I (n = 81) Period II (n = 97)
Fluid intake, mL/kg/d
DOL 7 106 ± 21 107 ± 20
DOL 14 117 ± 21 101 ± 23*
DOL 21 125 ± 22 107 ± 25*
DOL 28 120 ± 26 115 ± 21
Energy intake, kcal/kg/d
DOL 7 68 ± 18 70 ± 18
DOL 14 81 ± 20 77 ± 18
DOL 21 86 ± 21 83 ± 19
DOL 28 85 ± 20 87 ± 18
Renal function
Oliguric renal failure, n (%) 12 (15) 13 (13)
Nonoliguric renal dysfunction 12 (15) 21 (22)
Use of diuretic drugs, days 1.6 ± 1.4 2.1 ± 1.9*
Peak blood urea nitrogen level, mg/dL 33 ± 13 33 ± 11
Peak serum creatinine level, mg/dL 1.4 ± 0.5 1.4 ± 0.5
DOL, day of life.
*P < .05 compared with period I.
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